SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that is has secured €280m of funding to significantly expand and advance its clinical pipeline, including its lead asset SOT101, an IL-15 superagonist, and three new clinical programs until the end of 2023.

“We appreciate the successful track record of execution by the Company to this point and are confident that this funding will further enable SOTIO to continue building a unique, privately financed oncology company with a mature and diversified pipeline. SOTIO is a member of the PPF Group. SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries.

Sotio Secures €280M Of Funding To Expand And Advance Clinical Pipeline

Description

Company Information

Funding Insights

Sotio Secures €280M Of Funding To Expand And Advance Clinical Pipeline

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information